CombiMatrix Corporation (CBMX) Given Media Impact Rating of 0.10
Press coverage about CombiMatrix Corporation (NASDAQ:CBMX) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CombiMatrix Corporation earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 44.5032522473184 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of equities analysts have recently commented on the company. Ladenburg Thalmann Financial Services downgraded CombiMatrix Corporation from a “buy” rating to a “neutral” rating in a research report on Friday, August 4th. Aegis assumed coverage on CombiMatrix Corporation in a research report on Thursday, July 13th. They set a “buy” rating and a $8.10 price objective for the company.
Shares of CombiMatrix Corporation (NASDAQ:CBMX) traded up 0.70% during trading on Wednesday, hitting $7.20. The stock had a trading volume of 47,194 shares. CombiMatrix Corporation has a one year low of $2.15 and a one year high of $8.20. The company’s market cap is $21.01 million. The stock’s 50-day moving average price is $7.62 and its 200-day moving average price is $6.35.
CombiMatrix Corporation (NASDAQ:CBMX) last posted its earnings results on Thursday, August 3rd. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.11. CombiMatrix Corporation had a negative return on equity of 36.07% and a negative net margin of 15.53%. The business had revenue of $4.24 million during the quarter, compared to analyst estimates of $3.89 million. On average, equities research analysts forecast that CombiMatrix Corporation will post ($0.52) EPS for the current fiscal year.
WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/11/01/combimatrix-corporation-cbmx-given-media-impact-rating-of-0-10.html.
About CombiMatrix Corporation
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.
Receive News & Ratings for CombiMatrix Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.